Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1997 3
1998 7
1999 5
2000 12
2001 7
2002 16
2003 20
2004 10
2005 12
2006 26
2007 37
2008 40
2009 47
2010 45
2011 45
2012 56
2013 44
2014 59
2015 76
2016 58
2017 63
2018 68
2019 78
2020 76
2021 98
2022 79
2023 43
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

887 results

Results by year

Filters applied: . Clear all
Page 1
Intermediate-risk Prostate Cancer: Stratification and Management.
Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. Preisser F, et al. Among authors: graefen m. Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14. Eur Urol Oncol. 2020. PMID: 32303478 Review.
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J. Gerhauser C, et al. Among authors: graefen m. Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016. Cancer Cell. 2018. PMID: 30537516 Free PMC article.
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: graefen m. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34054128 Free PMC article. Review.
A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update.
Walz J, Epstein JI, Ganzer R, Graefen M, Guazzoni G, Kaouk J, Menon M, Mottrie A, Myers RP, Patel V, Tewari A, Villers A, Artibani W. Walz J, et al. Among authors: graefen m. Eur Urol. 2016 Aug;70(2):301-11. doi: 10.1016/j.eururo.2016.01.026. Epub 2016 Feb 2. Eur Urol. 2016. PMID: 26850969 Review.
Eine randomisierte, offene, Multizenterstudie zum Einsatz von Cabazitaxel versus einem Androgenrezeptor (AR)-gerichteten Präparat (Abirateron oder Enzalutamid) bei Patienten mit mCRPC nach Vorbehandlung mit Docetaxel und frühem Nicht-Ansprechen nach AR-gerichtetem Präparat (CARD) – Studie AP 97/17 der AUO.
Rexer H, Graefen M, Wülfing C. Rexer H, et al. Among authors: graefen m. Aktuelle Urol. 2018 Jun;49(3):222-224. doi: 10.1055/a-0596-4618. Epub 2018 May 22. Aktuelle Urol. 2018. PMID: 29788522 German. No abstract available.
Reply by Authors.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: graefen m. J Urol. 2021 Jul;206(1):79. doi: 10.1097/JU.0000000000001695.03. Epub 2021 Apr 6. J Urol. 2021. PMID: 33820427 No abstract available.
Phase-III-Studie beim lokalen oder lokal fortgeschrittenen Prostatakarzinom: Randomisierte, doppelblinde, Placebo-kontrollierte Phase 3 Studie zu Apalutamide in Patienten mit lokalem Hoch-Risiko-Prostatakarzinom oder lokal fortgeschrittenem Prostatakarzinom, die eine primäre Radiotherapie erhalten (ATLAS) – Studie AP 90/15 der AUO.
Rexer H, Graefen M Prof Dr, Grimm MO Prof Dr. Rexer H, et al. Among authors: graefen m prof dr. Aktuelle Urol. 2017 Dec;48(6):520-521. doi: 10.1055/s-0043-119917. Epub 2017 Dec 7. Aktuelle Urol. 2017. PMID: 29216658 Clinical Trial. German. No abstract available.
Reply by Authors.
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Fossati N, et al. Among authors: graefen m. J Urol. 2020 Aug;204(2):302. doi: 10.1097/JU.0000000000000800.03. Epub 2020 May 19. J Urol. 2020. PMID: 32427046 No abstract available.
AUTHOR REPLY.
Knipper S, Graefen M, Karakiewicz PI. Knipper S, et al. Among authors: graefen m. Urology. 2019 Nov;133:142-143. doi: 10.1016/j.urology.2019.05.055. Urology. 2019. PMID: 31706414 No abstract available.
887 results